Trials / Recruiting
RecruitingNCT06828354
A Study of SHR-A1811 in Subjects With Ovarian Cancer
An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | SHR-A1811. |
| DRUG | Paclitaxel Injection | Paclitaxel Injection. |
| DRUG | Doxorubicin Hydrochloride Liposome Injection | Doxorubicin Hydrochloride Liposome Injection. |
| DRUG | Gemcitabine Hydrochloride for Injection | Gemcitabine Hydrochloride for Injection. |
| DRUG | Topotecan Hydrochloride for Injection | Topotecan Hydrochloride for Injection. |
Timeline
- Start date
- 2025-03-13
- Primary completion
- 2027-05-01
- Completion
- 2027-12-01
- First posted
- 2025-02-14
- Last updated
- 2025-03-24
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06828354. Inclusion in this directory is not an endorsement.